Recent advancements in immunotherapy have transformed cancer treatment, particularly with the introduction of immune checkpoint inhibitors (ICIs), such as anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) inhibitors. Here, CD274 is linked to cancer.